Nutriband Inc（NTRB）资讯与事件NTRBNutriband Inc

Nutriband Files Patent Application for Aversa Technology

Nutriband announced that it has filed a non-provisional utility patent application with the U.S. Patent and Trademark Office, or USPTO, to further strengthen Nutriband's intellectual property protection for its Aversa abuse deterrent transdermal technology. This new patent application covers improved aversive formulations and coating application methods to enhance the abuse deterrent properties of Nutriband's Aversa transdermal technology and make it even more difficult to defeat. If this new patent is subsequently granted, it could significantly extend the patent protection for products that utilize Nutriband's Aversa abuse deterrent technology as the statutory patent term of a U.S. patent is 20 years from the non-provisional filing date. If granted, the worldwide, or PCT, patent protection for Aversa-based products such as Aversa Fentanyl could be extended to 2046.

Nutriband Appoints Robert O'Neill to Advisory Board

Nutriband announced the appointment of Robert O'Neill to its Advisory Board. O'Neill is a former U.S. Navy SEAL, New York Times best-selling author, and speaker on leadership and resilience.

Nutriband Receives Trademark Publication Notice from USPTO

Nutriband announced that it has received a notice of publication from the United States Patent and Trademark Office, or USPTO, for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Trademarks will be published in the USPTO Trademark Official Gazette. If no objections are filed during the 30-day opposition period, the USPTO is expected to issue a Notice of Allowance. Nutriband intends to secure full intellectual property rights for its commercial brand names in the United States and internationally. The proposed brand name and product labeling will be submitted to the FDA and other international regulatory agencies for review and approval.